Md. Perloff et al., Midazolam and triazolam biotransformation in mouse and human liver microsomes: Relative contribution of CYP3A and CYP2C isoforms, J PHARM EXP, 292(2), 2000, pp. 618-628
Citations number
40
Categorie Soggetti
Pharmacology & Toxicology
Journal title
JOURNAL OF PHARMACOLOGY AND EXPERIMENTAL THERAPEUTICS
Midazolam (MDZ) and triazolam (TRZ) hydroxylation, reactions considered to
be cytochrome P-4503A (CYP3A)-mediated in humans, were examined in mouse an
d human liver microsomes. In both species, alpha- and 4-hydroxy metabolites
were the principal products. Western blotting with anti-CYP3A1 antibody de
tected a single band of immunoreactive protein in both human and mouse samp
les: 0.45 +/- 0.12 and 2.02 +/- 0.24 pmol/mg protein (mean +/- S.E., n = 3)
, respectively. Ketoconazole potently inhibited MDZ and TRZ metabolite form
ation in human liver microsomes (IC50 range, 0.038-0.049 mu M). Ketoconazol
e also inhibited the formation of both TRZ metabolites and of 4-OH-MDZ form
ation in mouse liver microsomes (IC50 range, 0.0076-0.025 mu M). However, k
etoconazole (10 mu M) did not produce 50% inhibition of alpha-OH-MDZ format
ion in mouse liver microsomes. Anti-CYP3A1 antibodies produced concentratio
n-dependent inhibition of MDZ and TRZ metabolite formation in human liver m
icrosomes and of TRZ metabolite and 4-OH-MDZ formation in mouse liver micro
somes to less than 20% of control values but reduced alpha-OH-MDZ formation
to only 66% of control values in mouse liver microsomes. Anti-CYP2C11 anti
bodies inhibited alpha-OH-MDZ metabolite formation in a concentration-depen
dent manner to 58% of control values in mouse liver microsomes but did not
inhibit 4-OH-MDZ formation. Thus, TRZ hydroxylation appears to be CYP3A spe
cific in mice and humans. alpha-Hydroxylation of MDZ has a major CYP2C comp
onent in addition to CYP3A in mice, demonstrating that metabolic profiles o
f drugs in animals cannot be assumed to reflect human metabolic patterns, e
ven with closely related substrates.